Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
PAVmed ( (PAVM) ) has issued an announcement.
On December 30, 2025, PAVmed Inc. announced that it will implement a 1-for-30 reverse stock split of its common stock, effective January 2, 2026, following shareholder approval at a special meeting on December 5, 2025 and board approval of the ratio on December 8, 2025. The move, which also reduces authorized common shares from 250 million to 25 million, is aimed at lifting PAVmed’s share price above Nasdaq’s $1.00 minimum bid requirement after a prolonged period of non-compliance, and will proportionately adjust outstanding options, convertible securities and equity plan share reserves while rounding up any fractional shares to the nearest whole share; the company’s Nasdaq ticker will remain PAVM, though its CUSIP number will change.
The most recent analyst rating on (PAVM) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on PAVmed stock, see the PAVM Stock Forecast page.
Spark’s Take on PAVM Stock
According to Spark, TipRanks’ AI Analyst, PAVM is a Neutral.
PAVmed’s overall stock score is primarily impacted by its financial challenges, including persistent losses and negative cash flows. Technical indicators show a bearish trend, and valuation metrics are weak due to unprofitability. The earnings call provided some positive strategic updates, but ongoing challenges in revenue growth and debt restructuring remain significant concerns.
To see Spark’s full report on PAVM stock, click here.
More about PAVmed
PAVmed Inc. is a diversified commercial-stage medical technology company operating across medical devices, diagnostics and digital health. Its key subsidiaries include Lucid Diagnostics, which markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer, and Veris Health, a digital health business developing remote patient monitoring solutions and an implantable physiological monitor to support personalized cancer care through its Veris Cancer Care Platform.
Average Trading Volume: 520,667
Technical Sentiment Signal: Sell
Current Market Cap: $8.58M
See more data about PAVM stock on TipRanks’ Stock Analysis page.